Dr Reddy#39;s Labs trades lower despite robust Q3 as Credit Suisse flags EBITDA worries
- Hot Stocks
admin
- 0
- 1 minute read
According to Credit Suisse, Suboxone still constitutes about 7 percent of Dr Reddy#39;s Labs#39; base EBITDA, and the entry of Apotex could potentially impact 40 percent of DRL#39;s EBITDA from Suboxone or 3 percent of consolidated EBITDA.
:max_bytes(150000):strip_icc():format(jpeg)/TheBenefitsofa403bPlan1-5f6ba60a4831453787b01d8d3d5e6dd3.png "The Benefits of a 403(b) Plan")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-913439122-01b729815ee64a5d976f25aef0c27619.jpg "How To Apply for a Personal Loan in 5 Steps in 2024")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1401715004-3d0b3676f8e44292bbf948383470dc1c.jpg "How to Find a ,000 Personal Loan")
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1360192311-be3affe79d19438882ada6b7f4a039ef.jpg "<div>From Then to Now: Inflation's Effects Over 25 Years</div>")